U.S. Markets closed

Matthew Lehman, the CEO of Prima BioMed Ltd. (PBMD), Interviews with The Wall Street Transcript

67 WALL STREET, New York - September 13, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Oncology Drug Development - Orphan Drugs - FDA Approval Process - Reimbursement Trends

Companies include: Prima BioMed Ltd. (PBMD) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the CEO of Prima BioMed Ltd. (PBMD) discusses company strategy and the outlook for this vital industry:

TWST: Give us your thoughts on what the market potential is for CVac, and what pricing and revenue opportunities do you see for Prima BioMed within that the overall market.

Mr. Lehman: Let's start with the big picture. This immune therapy space - or using products that can effect, manipulate or retrain our immune system - this is a large growing class in the industry. Currently, there are two approved products on the market, using the general scientific concepts of manipulating the immune system or the immune defenses of cancer. We do expect this space will grow significantly from these two products. A number of analysts have predicted it will become a multibillion dollar business in the next 10 years. For example, one analyst is predicting $35 billion per year in revenue in immune therapy by 2023. It's quite an interesting space.

If you take a look at where we are in development with our products in ovarian cancer, for example, we believe there is a significant market opportunity for a product such as CVac with approximately 35,000 patients diagnosed per year. As another example, if we take a look at colorectal cancer, there are approximately 180,000 patients diagnosed per year that would benefit from our product. There are approximately 100,000 patients per year diagnosed with triple- negative breast cancer. Pancreatic cancer certainly is more rare, with a few thousand patients per year being diagnosed. In this case, we are looking at...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.